Forbion led a $65m Series B round in Gate Bioscience.

Forbion, a venture capital firm, led a $65m Series B round in Gate Bioscience, a biotechnology company developing molecular gates, with participation from Eli Lilly And Company, Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV and ARCH Venture Partners. The funding will advance Gate’s lead molecular gate programs into the clinic and support the continued expansion of its differentiated molecular gate programs across inflammation and other therapeutic areas.